ClinicalTrials.gov record
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
ClinicalTrials.gov ID: NCT00573170
Public ClinicalTrials.gov record NCT00573170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Migraine Pain, Studies 1 and 2 of 2
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)
Study identification
- NCT ID
- NCT00573170
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 375 participants
Conditions and interventions
Conditions
Interventions
- TREXIMET® Drug
- Butalbital-containing Combination Medications (BCM) Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2008 (Type not available)
- Primary completion
- Aug 2009 (Actual)
- Completion
- Aug 2009 (Actual)
- Last update posted
- Dec 29, 2010
2008 – 2009
United States locations
- U.S. sites
- 107
- U.S. states
- 33
- U.S. cities
- 97
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Chandler | Arizona | 85224 | — |
| GSK Investigational Site | Gilbert | Arizona | 85234 | — |
| GSK Investigational Site | Litchfield Park | Arizona | 85340 | — |
| GSK Investigational Site | Mesa | Arizona | 85213 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Tempe | Arizona | 85283 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72201 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Anaheim | California | 92801 | — |
| GSk Investigational Site | Anaheim | California | 92805 | — |
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | Irvine | California | 92618 | — |
| GSK Investigational Site | Newport Beach | California | 92660 | — |
| GSK Investigational Site | Northridge | California | 91325 | — |
| GSK Investigational Site | Riverside | California | 92501 | — |
| GSK Investigational Site | Sacramento | California | 92585 | — |
| GSK Investigational Site | San Diego | California | 92108 | — |
| GSK Investigational Site | San Francisco | California | 94109 | — |
| GSK Investigational Site | Santa Monica | California | 90404 | — |
| GSK Investigational Site | Sherman Oaks | California | 91403 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | Westlake Village | California | 91361 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80909 | — |
| GSK Investigational Site | East Hartford | Connecticut | 06118 | — |
| GSK Investigational Site | New Britain | Connecticut | 06050 | — |
| GSK Investigational Site | Clearwater | Florida | 33755 | — |
| GSK Investigational Site | Daytona Beach | Florida | 32117 | — |
| GSK Investigational Site | DeLand | Florida | 32720 | — |
| GSK Investigational Site | Naples | Florida | 34102 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | Plantation | Florida | 33324 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33407-2450 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Rome | Georgia | 30165 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Suwanee | Georgia | 30024 | — |
| GSK Investigational Site | Chicago | Illinois | 60614 | — |
| GSK Investigational Site | Gurnee | Illinois | 60031 | — |
| GSK Investigational Site | Maywood | Illinois | 60153 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46256 | — |
| GSK Investigational Site | Paducah | Kentucky | 42003 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71101 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71103 | — |
| GSK Investigational Site | Biddeford | Maine | 04005 | — |
| GSK Investigational Site | Pikesville | Maryland | 21208 | — |
| GSk Investigational Site | Brockton | Massachusetts | 02301 | — |
| GSK Investigational Site | Springfield | Massachusetts | 01104 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48104 | — |
| GSK Investigational Site | Kalamazoo | Michigan | 49009 | — |
| GSK Investigational Site | Hattiesburg | Mississippi | 39401 | — |
| GSK Investigational Site | Springfield | Missouri | 65807 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Henderson | Nevada | 89014 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89119 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08002 | — |
| GSK Investigational Site | Ridgewood | New Jersey | 07550 | — |
| GSK Investigational Site | Stratford | New Jersey | 08084 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87108 | — |
| GSK Investigational Site | Albany | New York | 12205 | — |
| GSK Investigational Site | Albany | New York | 12206 | — |
| GSK Investigational Site | Brooklyn | New York | 11235 | — |
| GSK Investigational Site | Mount Vernon | New York | 10550 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | New York | New York | 10022 | — |
| GSK Investigational Site | Orchard Park | New York | 14127 | — |
| GSK Investigational Site | Schenectady | New York | 12308 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | The Bronx | New York | 10461 | — |
| GSK Investigational Site | Valley Stream | New York | 11580 | — |
| GSK Investigational Site | Cary | North Carolina | 27518 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28204 | — |
| GSK Investigational Site | Greenville | North Carolina | 27858 | — |
| GSK Investigational Site | Hickory | North Carolina | 28601 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Bismarck | North Dakota | 58501 | — |
| GSK Investigational Site | Fargo | North Dakota | 58104 | — |
| GSK Investigational Site | Minot | North Dakota | 58704 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45227 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45245 | — |
| GSK Investigational Site | Cleveland | Ohio | 44122 | — |
| GSK Investigational Site | Columbus | Ohio | 43210 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Toledo | Ohio | 43614-5809 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Greensburg | Pennsylvania | 15601 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19114 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15236 | — |
| GSK Investigational Site | Warwick | Rhode Island | 02886 | — |
| GSK Investigational Site | Beaufort | South Carolina | 29902 | — |
| GSK Investigational Site | Charleston | South Carolina | 29412 | — |
| GSK Investigational Site | Simpsonville | South Carolina | 29681 | — |
| GSk Investigational Site | Rapid City | South Dakota | 57702 | — |
| GSK Investigational Site | Columbia | Tennessee | 38401 | — |
| GSK Investigational Site | Cordova | Tennessee | 38018 | — |
| GSK Investigational Site | Germantown | Tennessee | 38139 | — |
| GSK Investigational Site | Nashville | Tennessee | 37203 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | Dallas | Texas | 75234 | — |
| GSK Investigational Site | Houston | Texas | 77004 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | San Antonio | Texas | 78258 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84107 | — |
| GSK Investigational Site | Virginia Beach | Virginia | 23452 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00573170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2010 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00573170 live on ClinicalTrials.gov.